|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: April 2024
Volume 9 | Issue 4
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 95
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | FORMULATION, DEVELOPMENT AND EVALTUATION OF APREMILAST IMMEDIATE RELEASE TABLET FOR MANAGMENT OF PSORIATIC ARTHRITIS |
| Authors Name: | PRIYANKA SUSHILKUMAR SARNIKAR , HINGNE L.D , BAGWAN LATIF RASHID |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_197500
|
| Published Paper Id: | IJNRDTH00050 |
| Published In: | Volume 8 Issue 6, June-2023 |
| DOI: | |
| Abstract: | ABSTRACT: The aim of this research paper was to develop and evaluate an Apremilast immediate release tablet for the management of Psoriatic Arthritis by utilizing excipients and checking their compatibility with the API through preformulation studies. The tablets were formed using the direct compression method, and different trial batches were performed to check their activity.The preformulation studies showed that the selected excipients were compatible with the API, and the optimized formulation was found to have good flow and compressibility properties. The tablets were evaluated for their physical characteristics, including size, weight, and hardness. The in vitro dissolution studies were also conducted to assess the drug release profile of the developed tablets.The results of the study showed that the developed Apremilast immediate release tablets had excellent physical characteristics, with uniform size and weight. The in vitro dissolution studies indicated that the tablets had a quick release rate and met the required pharmacopoeial standards. The pharmacokinetic study revealed that the tablets exhibited rapid absorption, with a maximum plasma concentration achieved within 1 hour of administration.In conclusion, the developed Apremilast immediate release tablet utilizing excipients and preformulation studies has the potential to be an effective therapeutic option for the management of Psoriatic Arthritis. Further studies are required to investigate. Sometimes immediate onset of action is considered obligatory immediate release tablets are the final option. Recently immediate release tablets have started gaining popularity and acceptance as a drug delivery system, mainly because they are easy to administer and lead to better patient compliance. In the present work, we engage in discussion about formulation, development, and evaluation of immediate release tablets. An immediate release dosage form allows a manufacturer to extend market exclusivity. They are also a tool for expanding markets, extending product life cycles and generating opportunities. Pharmaceutical products designed for oral delivery and currently available on the prescription and over-the-counter markets are mostly the immediate release tablet. |
| Keywords: | |
| Cite Article: | "FORMULATION, DEVELOPMENT AND EVALTUATION OF APREMILAST IMMEDIATE RELEASE TABLET FOR MANAGMENT OF PSORIATIC ARTHRITIS", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 6, page no.773-816, June-2023, Available :http://www.ijnrd.org/papers/IJNRDTH00050.pdf |
| Downloads: | 000118763 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRDTH00050 Registration ID: 197500 Published In: Volume 8 Issue 6, June-2023 DOI (Digital Object Identifier): Page No: 773-816 Country: Beed, Maharashtra , India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRDTH00050 Published Paper PDF: https://www.ijnrd.org/papers/IJNRDTH00050 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn